Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if JBIO is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
34 top institutions tracked
Last 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoverySentiment: unknown
No recent insider trades detected.
Red flags: 0
151 filers reported a long position in JBIO for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| FMR LLC | $202.8M | 9.1M | +28.8% |
| Jupiter Topco LLC | $139.4M | 6.3M | — |
| Fairmount Funds Management LLC | $101.2M | 4.6M | Unchanged |
| RA CAPITAL MANAGEMENT, L.P. | $81.6M | 3.7M | Unchanged |
| Venrock Adviser, LLC | $71.6M | 3.2M | Unchanged |
| Bellevue Group AG | $67.9M | 3.1M | -12.7% |
| Paradigm Biocapital Advisors LP | $63.5M | 2.9M | New |
| BlackRock, Inc. | $62.2M | 2.8M | +21.1% |
| FRANKLIN RESOURCES INC | $62M | 2.8M | New |
| STATE STREET CORP | $51.9M | 2.3M | +256.2% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.